Global Antifungal Drugs Market
Antifungal drugs are used in the treatment of various fungal infections, by killing the fungal cell by cell breaking and leak out the contents of cell and leads to the cell death. They also act by preventing the cell growth with minimal toxic adverse effects to the body. Fungal infections occur due to unhygienic, unclean, and dampness in the environment. Fungal infections mainly caused by the microorganisms entering into the epithelial tissue. Fungi utilizes the keratin and cause infection of the hair, skin, and nail Anti- fungal drugs enables to treat fungal infections like athlete’s foot, ringworm, vaginal thrush, and nail infection. Systemic fungal infections are caused due to inhalation or indigestion of fungal spores and cause fungal pneumonia.
The antifungal drugs market is anticipated to increase at a significant CAGR over the forecast period due to rise in global population, and unhygienic environment. Burgeoning prevalence of infectious diseases, hospital acquired infections (nosocomial infections) coupled with rising awareness about the myriad fungal infections, and rising awareness of over-the-counter (OTC) antifungal drugs are the key factors expected to fuel the growth of the antifungal drugs market. In addition, rise in the R&D expenditure, increased funding from private and public sector for dermal infections, higher prevalence of chronic conditions, including HIV and cancer, rising of immunocompromised population, and increase in awareness by organizing patient education program are boosted the growth of antifungal drugs market over forecast period. However, the alternative therapies for fungal infections, patent expiries of branded drugs and availability of counterfeit drugs, stringent government policies, and adverse drug reactions of antifungal drugs are the major restraints for the growth of antifungal drugs over forecasting period.
The global antifungal drugs market is segmented on the basis of drug class, route of administration, therapeutic indication, and distribution channel
Based on the drug class, the market is segmented into the following:
Based on the route of administration, the market is segmented into the following:
Based on therapeutic indications, the market is segmented into the following:
Based on distribution channel, the market is segmented into the following:
- Retail pharmacies
- Hospital pharmacies
- Drug stores
- Online pharmacies
The global antifungal drugs market is in blooming stage, several local and international players are actively involved in the development of antifungal drugs. The collaboration of government organizations for the increase in the awareness about fungal infections is expected to unlock the potential of antifungal drugs market. For instance, In November 2013, the CDC entered into a collaborative agreement with the National Health Ministry to enhance the treatment rates of communicable diseases in emerging countries, such as Brazil and India. Major acquisitions and collaborations among companies to commercialize antifungal drugs, mergers, launching of new products, and product approvals from various drug regulatory bodies such as U.S. FDA and EMEA enable increase the global antifungal drugs market growth. For instance, in October 2009, Mylan inks licensing deal with Pfizer to start selling a U.S. generic version of Pfizer’s Vfend antifungal drug. The increase in the prevalence of fungal infections also boosts the antifungal drugs market growth. According to Centres for Disease Control and Prevention (CDC), around one million people get infected worldwide by cryptococcal meningitis, which is a brain infection caused by fungus Cryptococcus and it subsequently leads to 625,000 deaths.
Geographically, antifungal drugs market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Middle East and Africa, and Latin America. North America holds the largest share in the antifungal drugs market followed by Europe and Asia-Pacific, owing to increasing patient awareness, R&D expenditure for development of new drugs, and increase in prevalence rate of fungal infections in U.S. (According to Centre for Disease Control and Prevention (CDC) approximately 46,000 new cases of candidiasis occur every year in U.S.) Europe holds a major market share in anti-fungal drugs market attributed to increase in the prevalence rate of fungal infections in Europe and the development of antifungal biopharmaceuticals. Asia Pacific accounts for a significant growth owing to burgeoning consumer base and development in the economies of China and India. Rising income per capita, increasing awareness about the personal hygiene, and increase in healthcare expenditure might fuel the antifungal drugs market in Asia-Pacific region.
Some of the players in antifungal drugs market are Pfizer, Inc. (U.S.), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), Bayer AG (Germany), Astellas Pharma, Inc. (Japan), GlaxoSmithKline plc. (U.K.), Mylan N.V. (U.S.), Tecan Group (Switzerland), and AureoGen Biosciences Inc. (U.S.), to name a few.
- In February 2016, AureoGen Biosciences Inc. announced a licensing agreement with Merck, known as MSD for the development of medicines for infectious disease, including systemic fungal infections
- In December 2016, The U.S. FDA has approved Eucrisa (Crisaborole) ointment manufactured by Pfizer to treat eczema
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario